Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 7 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Somalogic Operating Co. Inc. has 9 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 9 examiners and 9 art units, indicating complete distribution across separate examination channels. This profile calls for rigorous centralized docket control, but each response must be developed independently because no examiner or art unit carries more than one identified action.
HOFFMAN, ALEXANDER JOSEPH is the busiest examiner, with 1 pending matter. The examiner handles one file, while the remaining matters are distributed across other assignments. Counsel can coordinate platform terminology, experimental support, and claim objectives across the portfolio, while treating each office action as a distinct prosecution problem.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (14%) |
| §101 + other | 3 (43%) |
| §103 only | 2 (29%) |
| Multi-statute (no §101) | 1 (14%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOFFMAN, ALEXANDER JOSEPH | 1 | 0.0% | +0.0% |
| KRISHNAN, GANAPATHY | 1 | 52.7% | +1.3% |
| GOUGH, TIFFANY MAUREEN | 1 | 31.7% | +46.5% |
| HAYES, JONATHAN EDWARD | 1 | 36.3% | +23.5% |
| WHALEY, PABLO S | 1 | 25.0% | +21.3% |
| DUNN, MCKENZIE A | 1 | 54.2% | +57.3% |
| POHNERT, STEVEN C | 1 | 12.5% | +18.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18693210 | Lung Cancer Prediction and Uses Thereof | HOFFMAN, ALEXANDER JOSEPH | — |
| 17480698 | Lung Cancer Biomarkers and Uses Thereof | HAYES, JONATHAN EDWARD | — |
| 17297669 | Methods For Determining Disease Risk Combining Downsampling of Class-Imbalanced Sets With Survival Analysis | WHALEY, PABLO S | — |
| 17287959 | Methods for Sample Quality Assessment | DUNN, MCKENZIE A | — |
| 16973734 | IMPROVED PROTEOMIC MULTIPLEX ASSAYS | POHNERT, STEVEN C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17637128 | Cardiovascular Risk Event Prediction and Uses Thereof | GOUGH, TIFFANY MAUREEN | 21d |
| 17480698 | Lung Cancer Biomarkers and Uses Thereof | HAYES, JONATHAN EDWARD | — |
| 17297669 | Methods For Determining Disease Risk Combining Downsampling of Class-Imbalanced Sets With Survival Analysis | WHALEY, PABLO S | — |
| 17287959 | Methods for Sample Quality Assessment | DUNN, MCKENZIE A | — |
| 16973734 | IMPROVED PROTEOMIC MULTIPLEX ASSAYS | POHNERT, STEVEN C | — |
| Art Unit | Apps |
|---|---|
| 1677 | 1 |
| 1693 | 1 |
| 1651 | 1 |
| 1685 | 1 |
| 3619 | 1 |
| 1678 | 1 |
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18693210 | Lung Cancer Prediction and Uses Thereof | HOFFMAN, ALEXANDER JOSEPH | 1677 | §101§102§103§112 | Non-Final OA | — | Pending | Mar 19, 2024 |
| 18477649 | Spin-Labeled Nucleosides and Phosphoramidites | KRISHNAN, GANAPATHY | 1693 | §103 | Final Rejection | — | Pending | Sep 29, 2023 |
| 17637128 | Cardiovascular Risk Event Prediction and Uses Thereof | GOUGH, TIFFANY MAUREEN | 1651 | §103 | Final Rejection | 21d | Pending | Feb 22, 2022 |
| 17480698 | Lung Cancer Biomarkers and Uses Thereof | HAYES, JONATHAN EDWARD | 1685 | §101§112 | Non-Final OA | — | Pending | Sep 21, 2021 |
| 17297669 | Methods For Determining Disease Risk Combining Downsampling of Class-Imbalanced Sets With Survival Analysis | WHALEY, PABLO S | 3619 | §101§103§112 | Final Rejection | — | Pending | May 27, 2021 |
| 17287959 | Methods for Sample Quality Assessment | DUNN, MCKENZIE A | 1678 | §101 | Final Rejection | — | Pending | Apr 22, 2021 |
| 16973734 | IMPROVED PROTEOMIC MULTIPLEX ASSAYS | POHNERT, STEVEN C | 1683 | §103§112 | Final Rejection | — | Pending | Dec 09, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSomalogic Operating Co. Inc. has 7 pending office actions as of October 2026, spread across 7 art units and 7 examiners.
Alexander Joseph Hoffman has the most, with 1 of Somalogic Operating Co. Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
